Stay updated on Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.

Latest updates to the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference2%
- Check24 days agoChange DetectedTerminology updated from 'Plasma cell myeloma' to 'Multiple myeloma' and page version bumped from v3.0.2 to v3.1.0.SummaryDifference0.1%
- Check38 days agoChange DetectedThe page revision was updated from v3.0.1 to v3.0.2, and the 'Back to Top' link was removed.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%
- Check52 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as new medical terms related to plasma cell myeloma and various compounds. Notably, several previous terms related to multiple myeloma treatments have been removed.SummaryDifference2%
- Check67 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
Stay in the know with updates to Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.